Faruqi & Faruqi Alerts Investors About RGNX Class Action Lawsuit Deadline
On April 4, 2026, noted securities law firm Faruqi & Faruqi, LLP took to the forefront of investor advocacy by announcing critical information regarding REGENXBIO Inc. (NASDAQ: RGNX) and an impending class action lawsuit against the company. This action arises from allegations that have surfaced regarding potential misrepresentations made by REGENXBIO and its executives concerning the safety and efficacy of their gene therapy products, particularly RGX-111 and RGX-121. The firm reminds those who acquired REGENXBIO securities between February 9, 2022, and January 27, 2026, to act before the April 14, 2026, deadline for filing as lead plaintiff in this federal securities class action.
The impetus for this action was triggered on January 28, 2026, when REGENXBIO publicly disclosed that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on their investigational gene therapy, RGX-111. This decision was based on a troubling preliminary analysis of a case where neoplasm (an intraventricular CNS tumor) was identified in one of the trial participants. Furthermore, this situation extended to RGX-121, intended for treating MPS II, as the FDA cited similarities in study populations and potential risks. The immediate financial repercussions for REGENXBIO were staggering; the company witnessed a significant drop in its stock price by $2.40, reflecting a 17.9% decrease, culminating in a closing price of $11.01 following this announcement.
Faruqi & Faruqi has built a formidable reputation in the legal landscape with a storied history of recovering substantial amounts for investors, having recovered hundreds of millions of dollars since its inception in 1995. Investors who may have faced losses due to their involvement with REGENXBIO are encouraged to reach out to the firm's partner, James (Josh) Wilson, at 877-247-4292 or 212-983-9330, Ext. 1310, to discuss potential legal options. They also urge anyone with pertinent information regarding the company's practices to come forward, including whistleblowers, former employees, shareholders, and others.
The role of a lead plaintiff is crucial in such class action lawsuits. In essence, the court will appoint the lead plaintiff as the representative for all class members, who will guide and oversee the litigation process on their behalf. It's important to note that an investor's choice to serve as lead or remain an absent class member will not impact their eligibility to partake in any potential recovery. For those seeking more detailed information on the ongoing legal proceedings against REGENXBIO, materials can be accessed through the law firm's website, promoting transparency and providing insights into this significant legal matter.
In conclusion, the upcoming deadline places significant importance on actions taken by affected investors. As the timeline progresses, those impacted by REGENXBIO's disclosures and subsequent stock price plunge have a limited window to seek legal recourse. Staying informed and proactive is vital for reaching any favorable resolutions concerning the allegations against REGENXBIO.
The impetus for this action was triggered on January 28, 2026, when REGENXBIO publicly disclosed that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on their investigational gene therapy, RGX-111. This decision was based on a troubling preliminary analysis of a case where neoplasm (an intraventricular CNS tumor) was identified in one of the trial participants. Furthermore, this situation extended to RGX-121, intended for treating MPS II, as the FDA cited similarities in study populations and potential risks. The immediate financial repercussions for REGENXBIO were staggering; the company witnessed a significant drop in its stock price by $2.40, reflecting a 17.9% decrease, culminating in a closing price of $11.01 following this announcement.
Faruqi & Faruqi has built a formidable reputation in the legal landscape with a storied history of recovering substantial amounts for investors, having recovered hundreds of millions of dollars since its inception in 1995. Investors who may have faced losses due to their involvement with REGENXBIO are encouraged to reach out to the firm's partner, James (Josh) Wilson, at 877-247-4292 or 212-983-9330, Ext. 1310, to discuss potential legal options. They also urge anyone with pertinent information regarding the company's practices to come forward, including whistleblowers, former employees, shareholders, and others.
The role of a lead plaintiff is crucial in such class action lawsuits. In essence, the court will appoint the lead plaintiff as the representative for all class members, who will guide and oversee the litigation process on their behalf. It's important to note that an investor's choice to serve as lead or remain an absent class member will not impact their eligibility to partake in any potential recovery. For those seeking more detailed information on the ongoing legal proceedings against REGENXBIO, materials can be accessed through the law firm's website, promoting transparency and providing insights into this significant legal matter.
In conclusion, the upcoming deadline places significant importance on actions taken by affected investors. As the timeline progresses, those impacted by REGENXBIO's disclosures and subsequent stock price plunge have a limited window to seek legal recourse. Staying informed and proactive is vital for reaching any favorable resolutions concerning the allegations against REGENXBIO.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.